CINECA IRIS Institutional Research Information System

LEONE, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.881
EU - Europa 3.523
AS - Asia 3.424
SA - Sud America 122
OC - Oceania 79
AF - Africa 35
Continente sconosciuto - Info sul continente non disponibili 12
Totale 13.076
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.728
CN - Cina 1.935
IT - Italia 885
DE - Germania 469
JP - Giappone 371
FR - Francia 338
GB - Regno Unito 336
SG - Singapore 320
IE - Irlanda 274
ES - Italia 234
SE - Svezia 212
IN - India 148
KR - Corea 131
FI - Finlandia 126
CA - Canada 121
UA - Ucraina 116
VN - Vietnam 89
BR - Brasile 88
TR - Turchia 81
TW - Taiwan 81
PL - Polonia 75
HK - Hong Kong 73
CH - Svizzera 69
AU - Australia 62
NL - Olanda 60
BE - Belgio 59
GR - Grecia 51
RU - Federazione Russa 49
ID - Indonesia 46
TH - Thailandia 39
MX - Messico 26
CZ - Repubblica Ceca 25
RO - Romania 25
SA - Arabia Saudita 23
AT - Austria 22
IR - Iran 21
DK - Danimarca 20
PT - Portogallo 20
NZ - Nuova Zelanda 17
EG - Egitto 14
HU - Ungheria 13
IL - Israele 13
CL - Cile 12
MY - Malesia 11
AR - Argentina 9
EU - Europa 9
PK - Pakistan 9
HR - Croazia 8
LB - Libano 6
AM - Armenia 5
CO - Colombia 5
KE - Kenya 5
PE - Perù 5
PH - Filippine 5
SI - Slovenia 5
EE - Estonia 4
LU - Lussemburgo 4
NO - Norvegia 4
OM - Oman 4
ZA - Sudafrica 4
AP - ???statistics.table.value.countryCode.AP??? 3
GE - Georgia 3
IS - Islanda 3
JO - Giordania 3
MK - Macedonia 3
SK - Slovacchia (Repubblica Slovacca) 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GH - Ghana 2
IM - Isola di Man 2
PR - Porto Rico 2
QA - Qatar 2
TG - Togo 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
BT - Bhutan 1
EC - Ecuador 1
ET - Etiopia 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
MU - Mauritius 1
NG - Nigeria 1
NI - Nicaragua 1
PA - Panama 1
PY - Paraguay 1
RS - Serbia 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 13.076
Salva come PNG Salva come JPEG
Città #
Beijing 532
Chandler 473
Fairfield 384
Houston 337
Shanghai 274
Dublin 271
Singapore 260
Ashburn 227
Woodbridge 208
Wilmington 203
Seattle 197
Ann Arbor 193
Redwood City 164
Torino 150
Cambridge 145
Dearborn 125
Villeurbanne 125
Guangzhou 121
Nyköping 113
Jacksonville 105
Santa Clara 103
Tokyo 103
Pisa 102
Princeton 94
Columbus 92
Nanjing 86
Medford 84
Milan 75
New York 65
Warsaw 64
Dong Ket 55
Zhengzhou 55
Boston 53
Wuhan 51
Chengdu 47
Taipei 47
Munich 46
Hangzhou 45
Duncan 41
London 41
San Diego 41
Jakarta 40
Paris 37
Madrid 36
Rome 36
Istanbul 35
Jinan 35
Hefei 34
Barcelona 30
Toronto 30
Brussels 29
Turin 29
Boardman 26
Chicago 26
Los Angeles 26
Norwalk 26
Seoul 25
Tianjin 24
Ottawa 22
Shenyang 22
Berlin 20
São Paulo 20
Aioicho 19
Amsterdam 19
Salt Lake City 19
Fremont 18
Phoenix 18
Philadelphia 17
Chongqing 16
Hong Kong 16
Mumbai 16
Hebei 15
Helsinki 15
Montreal 15
Nanchang 15
San Francisco 15
Shenzhen 15
Dallas 14
Silver Spring 14
Athens 13
Atlanta 13
Changsha 13
Nutley 13
Sydney 13
Manchester 12
Melbourne 12
Newbury Park 12
Pune 12
Rochester 12
San Mateo 12
Verona 12
Washington 12
Bangkok 11
Brno 11
Vancouver 11
Bari 10
Düsseldorf 10
Florence 10
Jiaxing 10
Riyadh 10
Totale 7.125
Salva come PNG Salva come JPEG
Nome #
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial 5.173
Emerging molecular target antagonists for the treatment of biliary tract cancer 666
A phase I dose-escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. 444
Potentially resectable metastatic colorectal cancer: An individualized approach to conversion therapy. 268
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study) 238
Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy 219
Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18 F-FDG PET and MRI radiomics features 198
Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor 170
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity 155
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. 151
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 148
Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma 148
The Role of Lung Metastasis Resection in Improving Outcome of Colorectal Cancer Patients: Results from a Large Retrospective Study. 148
Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology 142
Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: A case report 132
Fluoropyrimidine-induced cardiotoxicity 131
Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR 131
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma 122
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. 121
HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives 121
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: A multicenter survey and pooled analysis with published data 120
Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line 119
Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine 117
Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients 114
The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005 110
PHASE II TRIAL OF PANITUMUMAB IN COMBINATION WITH OXALIPLATIN AND CAPECITABINE CHEMOTHERAPY AS 1ST LINE THERAPY IN PATIENTS WITH COLORECTAL CANCER AND ADVANCED LIVER METASTASES: THE METAPAN STUDY 108
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas 107
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. 102
Bone metastases in biliary cancers: A multicenter retrospective survey 101
Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer? 100
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 99
Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab 97
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases: The MetaPan study. 93
Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives 93
Antitumor activity of Src inhibitor Saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. 89
High prevalence of hepatitis C virus (HCV) genotype 2 in Italian patients with chronic liver disease. 86
Rationale for the use of metronomic chemotherapy in gastrointestinal cancer 84
[Diagnosis of neoplastic ascites: combined use of albumin gradient between serum and ascites and cholesterol in ascitic fluid] 81
Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient 79
Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction. 78
Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR. 78
Diagnostic paracentesis. A two-step approach. 75
Epidemiological and virological analysis of couples infected with hepatitis C virus. 75
GAS6, the ligand of Axl and Rse receptors, is expressed in hematopoietic tissue but lacks mitogenic activity. 74
LONG-TERM SURVIVAL OF PATIENTS WITH RESECTION OF PULMONARY METASTASES FROM COLORECTAL NEOPLASMS AS COMPARED TO NOT RESECTED ONES. A RETROSPECTIVE STUDY ON PATIENTS FOLLOWED FROM THE TIME OF FIRST RECURRENCE 74
Biliary tract carcinomas: From chemotherapy to targeted therapy. 74
Assessment of a HER2 scoring system for colorectal cancer: Results from a validation study 70
Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors 69
Capecitabine with/without mitomycin C: Results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma 66
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 64
Evaluation of iron status in patients with chronic hepatitis C. 63
Adjuvant chemotherapy and follow-up 63
A novel multidrug‐resistant cell line from an italian intrahepatic cholangiocarcinoma patient 60
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 59
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study 59
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 59
Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy 57
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 56
Linifanib: Current status and future potential in cancer therapy 55
Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients 54
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 54
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center 53
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 51
Outcome of metastatic colorectal cancer: analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach 51
Targeted agents: how can we improve the outcome in biliary tract cancer? 50
Phlebotomy reduces serum procollagen III peptide levels in patients with chronic hepatitis C. 49
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 49
“Shades of Gray” in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria: Debated indications for surgery in pancreatic cancer 49
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 48
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy 47
Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. 45
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 45
Hepatitis C virus (HCV) hypervariable region 1 complexity does not correlate with severity of liver disease, HCV type, viral load or duration of infection. 42
Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. 41
Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. 41
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 41
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 40
Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma 40
Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: A single institutional experience. 36
Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma 36
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 35
Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience 34
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 33
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 28
Fluoropyrimidine‑induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT) 28
Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience 24
Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy 22
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 15
Abstract 2848: Radiographic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer 10
Totale 13.444
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.282
article - articoli 0
book - libri 0
conference - conferenze 515
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.797
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.547 0 0 0 0 195 282 200 198 213 192 153 114
2020/20211.620 111 126 146 136 138 101 137 99 166 138 131 191
2021/20221.652 130 138 96 108 130 95 133 145 90 92 286 209
2022/20231.882 191 173 71 171 155 341 146 125 197 90 137 85
2023/20241.412 143 176 109 113 115 145 101 117 28 91 132 142
2024/2025924 73 188 163 224 276 0 0 0 0 0 0 0
Totale 13.444